4basebio

4basebio AG
legal form	Corporation
ISIN	DE000A2YN801
founding	1997
Seat	Heidelberg and Madrid (2014)
management	Heikki Lanckriet, (2018) David Roth (2018)
Number of employees	89 (2017)
sales	7.8 million euros (2017)
Branch	Pharmaceuticals
Website	www.4basebio.com

4basebio AG (2018 to 2019 Expedeon AG before Sygnis AG ) was a German-Spanish polymerase manufacturer with headquarters in Heidelberg and Madrid .

Companies

Company logo until 2018

The company, which is listed on the regulated market, develops polymerases and sells them in “kits” that are used for DNA sequencing and amplification . The IPO took place on August 11, 2001. In 2006, the operating business of the BASF subsidiary Axaron Bioscience AG, which was previously listed on the Neuer Markt as Lion Bioscience , was taken over.

Sygnis has consistently generated high losses since it was founded and was dependent on regular capital injections.

In August 2018, the name was changed from Sygnis AG to Expedeon AG with entry in the Mannheim commercial register.

At the beginning of January 2020, the sale of the operational core business to a US investor for around EUR 120 million was completed. An extraordinary general meeting approved the transaction on December 19, 2019. At the same time, the name was changed to 4basebio AG.

Supervisory board

Joseph M. Fernandez (Interim Chairman)
Pilar de la Huerta
Peter Llewellyn-Davies
Tim McCarthy
Trevor Jarman

former members:

Cristina Garmendia

Web links

Individual evidence

↑ "Products" on www.sygnis.com
↑ financial.de capital increase: Sygnis AG on the way to further milestones ( Memento of December 25, 2014 in the Internet Archive ). November 20, 2014, accessed November 20, 2014.
↑ At Sygnis Pharma, the money only lasts until the end of September. Rhein-Neckar-Zeitung , August 29, 2013.
↑ Expedeon AG (formerly SYGNIS AG) reports financial results for the first half of 2018 and successful name change (news with additional material) - dgap.de. Retrieved December 3, 2019 .
↑ rg: Prime Standard | 4basebio AG: Sale completed, Expedeon is history. In: Nebenwerte-magazin.com. January 2, 2020, accessed May 11, 2020 .
↑ kapitalus: Expedeon concludes a 120 million deal and becomes 4basebio AG. In: Kapitalmarktexperten.de. January 2, 2020, accessed on May 11, 2020 (German).
↑ https://investors.expedeon.com/wp-content/uploads/2019/03/20190314_Expedeon-SupervisoryBoardChanges_AdHoc_GER.pdf
↑ Expedeon AG: Announcement of the invitation to the Annual General Meeting on July 9, 2019 in Heidelberg. In: DGAP . May 19, 2019, accessed January 15, 2019 .

[1] "Products" on www.sygnis.com

[2] .de capital increase: Sygnis AG on the way to further milestones ( Memento of December 25, 2014 in the Internet Archive ). November 20, 2014, accessed November 20, 2014.

[3] At Sygnis Pharma, the money only lasts until the end of September. Rhein-Neckar-Zeitung , August 29, 2013.

[4] Expedeon AG (formerly SYGNIS AG) reports financial results for the first half of 2018 and successful name change (news with additional material) - dgap.de. Retrieved December 3, 2019 .

[5] rg: Prime Standard | 4basebio AG: Sale completed, Expedeon is history. In: Nebenwerte-magazin.com. January 2, 2020, accessed May 11, 2020 .

[6] talus: Expedeon concludes a 120 million deal and becomes 4basebio AG. In: Kapitalmarktexperten.de. January 2, 2020, accessed on May 11, 2020 (German).

[7] ttps://investors.expedeon.com/wp-content/uploads/2019/03/20190314_Expedeon-SupervisoryBoardChanges_AdHoc_GER.pdf

[8] Expedeon AG: Announcement of the invitation to the Annual General Meeting on July 9, 2019 in Heidelberg. In: DGAP . May 19, 2019, accessed January 15, 2019 .